Personalized Search
Displaying 1 - 20 of 49
The 10th International
Bone Marrow Failure
Bone Marrow Failure:
A condition that occurs when the bone marrow stops making enough healthy blood cells. The most common of these rare diseases are aplastic anemia, myelodysplastic syndromes (MDS) and paroxysmal nocturnal hemoglobinuria (PNH). Bone marrow failure can be acquired (begin any time in life) or can be…
Disease Scientific…
Webinar last updated
.
Thanks to the efforts of our AAMDSIF
bone marrow failure
bone marrow failure:
A condition that occurs when the bone marrow stops making enough healthy blood cells. The most common of these rare diseases are aplastic anemia, myelodysplastic syndromes (MDS) and paroxysmal nocturnal hemoglobinuria (PNH). Bone marrow failure can be acquired (begin any time in life) or can be…
community and…
Article last updated
.
Key Points
The number of autoHCT and alloHCT grew faster in Non-Hispanic African Americans and Hispanics compared to Non-Hispanic Whites.
Survival after autoHCT and alloHCT improved over time for all racial/ ethnic groups, though African Americans have worse outcomes.
There has been an increase in volume as well as improvement in overall survival (OS) after hematopoietic cell transplantation (…
Article last updated
.
Driven by his mother’s advice and his father’s memory, Richard M. Stone, MD, rose to become a global leader in leukemia care and research.
Growing up, Richard M. Stone, MD, thought he was going to be an attorney like his father, but his direction in life changed when he was 15. His father, Benjamin, developed kidney cancer when Stone was just 5 years old, and 10 years later, the disease…
Article last updated
.
PURPOSE:
Patients who have cancer have leveraged the Internet to gain a better understanding of their disease and connect across geographic boundaries with others facing the same challenges. Online cancer communities have developed into resources that highlight new research and evolving care pathways. Combined with increasing health literacy and social media, they have enabled some patients to…
Article last updated
.
June 2, 2022
- Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant –
- Omidubicel has
Orphan Drug
Orphan Drug:
A drug or biologic agent that treats a rare disease or condition. A disease is considered rare if fewer…
Article last updated
.
Abstract
Diagnosis of myelodysplastic syndrome (MDS) mainly relies on a manual assessment of the peripheral blood and
bone marrow
bone marrow:
The soft, spongy tissue inside most bones. Blood cells are formed in the bone marrow.
cell
morphology
morphology:
The study of the structure and form of an organism or one of its parts.
. The WHO guidelines suggest a visual screening…
Article last updated
.
The mRNA COVID-19 Vaccines Are Safe and Effective for Most Patients with Cancer
For most patients with cancer, the mRNA COVID-19 vaccines are safe and effective. This article explains the results of the first study that evaluated the safety and effectiveness of the mRNA vaccines in patients with solid cancers, such as lung, breast, or prostate cancer.
November 2021 – Lung Cancer
Laura Morgan
The…
Article last updated
.
Myelodysplastic syndromes
Myelodysplastic syndromes:
(my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone marrow does not work well, and the bone marrow cells fail to make enough healthy blood cells. Myelo refers to the bone marrow. Dysplastic means abnormal growth or development. People with MDS have low blood cell count for at…
(MDS) and
neutropenia…
Article last updated
.
MDS, or
Myelodysplastic syndromes
Myelodysplastic syndromes:
(my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone marrow does not work well, and the bone marrow cells fail to make enough healthy blood cells. Myelo refers to the bone marrow. Dysplastic means abnormal growth or development. People with MDS have low blood cell count for at…
, are a family of rare…
Basic page last updated
.
It is approved by the U.S. Food and Drug Administration (FDA) for treating acute promylocitic leukemia (APL). Currently, researchers are studying
arsenic trioxide
arsenic trioxide:
It is approved by the U.S. Food and Drug Administration (FDA) for treating acute promylocitic leukemia (APL). Currently, researchers are studying arsenic trioxide, as a single agent or in combination with…
Drug last updated
.
AAMDSIF provides educational materials for patients and healthcare professionals written in plain language and reviewed by highly respected and recognized medical doctors who are experts in
bone marrow failure
bone marrow failure:
A condition that occurs when the bone marrow stops making enough healthy blood cells. The most common of these rare diseases are aplastic anemia,…
Webform last updated
.
Since it was founded in 1983, AAMDSIF has partnered with clinicians and researchers to identify knowledge gaps in diagnosing and treating
bone marrow failure
bone marrow failure:
A condition that occurs when the bone marrow stops making enough healthy blood cells. The most common of these rare diseases are aplastic anemia, myelodysplastic syndromes (MDS) and paroxysmal nocturnal…
Webinar last updated
.
This symposium provides updates on the most recent advances in the
pathophysiology
pathophysiology:
Functional changes in the bodies that are associated with or result from disease or injury.
, diagnosis and clinical management of
bone marrow failure
bone marrow failure:
A condition that occurs when the bone marrow stops making enough healthy blood cells. The most common of…
Webinar last updated
.
The biennial Symposium will bring together physicians treating these diseases; laboratory researchers studying genetics, genomics, and
pathophysiology
pathophysiology:
Functional changes in the bodies that are associated with or result from disease or injury.
of
bone marrow failure
bone marrow failure:
A condition that occurs when the bone marrow stops making enough healthy…
Webinar last updated
.
This complimentary CME satellite symposium provided an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with AA, PNH, MDS, AML, MPN, and related myeloid malignancies. The overall goal of the program is to bring together leaders in disease research and clinical practice to explore solutions to improving the care…
Webinar last updated
.
AAMDSIF receives support from corporate partners who invest in advancing our mission. Thanks to their financial contributions, we are able to provide answers, support, and hope to patients, their families, and healthcare professionals entrusted with providing quality care.
AAMDSIF Corporate Partners provide financial and in-kind support of programming through sponsorships and grants.…
Basic page last updated
.
Mikkael A. Sekeres, MD, MS has been Medical Advisory Board Co-Chair since 2004. He is currently the Physician Liaison in Hematology and Chief of the Division of Hematology at the Sylvester Comprehensive Center at the University. Previously, Dr. Sekeres was the professor of medicine, director of the leukemia program, and Vice Chair for
Clinical Research
Clinical Research:
A type of…
Bio last updated
.
Dr. Abel received his MD and MPH from Columbia University in 2000. He completed his postgraduate training in internal medicine at Massachusetts General Hospital and his hematology/oncology fellowship at Dana-Farber Cancer Institute. In 2007, he joined Dana-Farber and is a member of the Hematologic Malignancies staff, as well as the Center for Outcomes and Policy Research.
Bio last updated
.